Efficacy of low dose apheresis platelet prophylactic infusion in hematological diseases: a retrospective study
| Autor: | Yan HU, Yu Qi, Yajuan WU, Huan LI, Li ZHANG, Hong XU, Tao PENG, Xinyu GAN |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Zhongguo shuxue zazhi, Vol 36, Iss 11, Pp 1008-1011 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1004-549X 1004-549x 55235778 |
| DOI: | 10.13303/j.cjbt.issn.1004-549x.2023.11.008&lang=en |
| Popis: | Objective To retrospectively analyze the efficacy of low dose apheresis platelet prophylactic infusion and explore its feasibility. Methods A total of 392 inpatients with platelet transfusion in our hospital from November 2020 to September 2021 were selected. The conventional dose (1 therapeutic dose) of apheresis platelet transfusion was set as the control group, and the low dose (0.5 therapeutic dose) as the experimental group. Platelet count before and after infusion, platelet elevation value (△PLT) and 24 h platelet count correction increase index (CCI) were observed, and the efficacy of low-dose platelet infusion was analyzed by disease type and gender. Results The △PLT value and 24h CCI effective infusion rate in control group were higher than those in experimental group: (16±16) ×109vs (7±10) ×109, 71.94% vs 60.46%, PAA (14±14) >ALL (13±12) >NHL (9±8) >MDS (7±6). In the experimental group, the △PLT (×109) was AA (11±18) >AML (8±8) >ALL (5±7) >NHL (5±7) >MDS (6±16). The 24h CCI was AML(163/188, 86.70%)>AA(23/32, 71.88%)>ALL(65/98, 66.33%)>MDS(9/17, 52.94%)>NHL(12/22, 51.55%) in the control group, and AML(133/188, 70.74%)>AA(19/32, 59.38%)>NHL(12/22, 51.55%)>ALL(47/98, 47.96%)>MDS(8/17, 47.06%) in the experimental group. The effective infusion rates of AML and ALL2 in the experimental groups were 70.74% (133/188) and 47.96% (47/98), respectively, significantly lower than 86.7% (163/188) and 66.33% (65/98) in the control group(P0.05). Conclusion Low-dose apheresis platelet prophylactic infusion can alleviate the between supply shortage, with an effective infusion rate of 60.46% (236/392), which has certain clinical application value. Patients with AML, AA or ALL were recommended with low dose platelets, while patients with MDS and NHL were not recommended. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|